The Connection Between Diabetes and Heart Disease That Most Patients Miss

Cardiology · 7 · March 12, 2026

Here's a statistic that shocks most people: roughly 65% of people with type 2 diabetes will die from heart disease or stroke. Not from diabetic ketoacidosis. Not from kidney failure. From cardiovascular disease. Diabetes doesn't just raise blood sugar. It accelerates atherosclerosis, promotes heart failure, and damages blood vessels in ways that make every other cardiac risk factor worse.

Why Diabetes Is a Cardiovascular Disease

Insulin resistance — the hallmark of type 2 diabetes — triggers a cascade of metabolic changes that attack the cardiovascular system from multiple angles simultaneously. It raises triglycerides and small dense LDL particles. It lowers HDL. It increases blood pressure through sodium retention and sympathetic activation. It promotes visceral fat accumulation, which produces inflammatory cytokines. And it damages the endothelium directly, impairing the blood vessels' ability to dilate and resist plaque formation.

Hyperglycemia itself is toxic to blood vessels. Elevated glucose promotes advanced glycation end-products (AGEs) that stiffen arterial walls and trigger inflammation. It increases oxidative stress. A landmark analysis in The Lancet showed that each 1% increase in HbA1c above 5.5% is associated with an 18% increase in cardiovascular events — and this relationship holds even in the pre-diabetic range.

Diabetic Cardiomyopathy: Heart Failure Without Blockages

Beyond atherosclerosis, diabetes causes structural changes to the heart muscle itself. Diabetic cardiomyopathy — characterized by myocardial fibrosis, stiffness, and impaired relaxation — can lead to heart failure even in the absence of coronary artery disease. The Framingham Heart Study found that diabetes increased the risk of heart failure 2-fold in men and 5-fold in women, independent of other risk factors.

This is one reason why HFpEF (heart failure with preserved ejection fraction) is so common in diabetic patients. The heart squeezes fine but can't relax and fill properly because the muscle is stiff from fibrosis and AGE deposition. Until recently, we had no effective treatment for this. SGLT2 inhibitors changed that.

SGLT2 Inhibitors: The Cardiac Revolution From Diabetes

Empagliflozin, dapagliflozin, and canagliflozin were developed as glucose-lowering drugs. But the cardiovascular trials revealed something remarkable. The EMPA-REG OUTCOME trial (2015, NEJM) showed empagliflozin reduced cardiovascular death by 38% in diabetic patients with established heart disease. Not cardiovascular events — cardiovascular death. A 38% reduction. That's an effect size larger than most cardiac medications achieve.

The DAPA-HF and EMPEROR-Reduced trials then showed these drugs reduce heart failure hospitalizations and death even in non-diabetic patients. The mechanism isn't fully understood — theories include favorable effects on cardiac metabolism (shifting the heart from fatty acid to ketone body oxidation), osmotic diuresis reducing preload, and direct anti-fibrotic effects on the myocardium.

SGLT2 inhibitors also protect the kidneys — reducing the progression of diabetic kidney disease by 30-40% (CREDENCE and DAPA-CKD trials). Since kidney disease itself accelerates cardiovascular disease, this creates a virtuous cycle of organ protection.

GLP-1 Receptor Agonists: Weight Loss That Saves Hearts

Semaglutide (Ozempic/Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity) are GLP-1 receptor agonists that lower glucose, promote weight loss of 10-15%, and — crucially — reduce major cardiovascular events. The SELECT trial (2023, NEJM) showed semaglutide 2.4mg reduced cardiovascular events by 20% in overweight/obese patients with cardiovascular disease, regardless of diabetes status. This drug class bridges the gap between metabolic health and cardiovascular protection.

What Every Diabetic Patient Should Know

If you have type 2 diabetes, your cardiovascular risk management is arguably more important than your glucose management. Target LDL below 70 mg/dL if you have any additional risk factor (most diabetics do). Blood pressure target: below 130/80. Ask your doctor about SGLT2 inhibitors or GLP-1 agonists — they should be part of your regimen if you have or are at risk for cardiovascular disease, regardless of your HbA1c level. And get screened: a coronary calcium score or CCTA can reveal subclinical disease that changes management.

Key Takeaways

- 65% of type 2 diabetic patients die from cardiovascular disease — it's the primary threat, not blood sugar

- SGLT2 inhibitors reduce cardiovascular death by 38% in diabetics with heart disease (EMPA-REG) and work in non-diabetics too

- GLP-1 receptor agonists (semaglutide) reduce cardiovascular events by 20% while promoting significant weight loss

- Diabetic cardiomyopathy causes heart failure independent of coronary artery blockages — HFpEF is the common presentation

- Every diabetic patient should have aggressive LDL and blood pressure targets, not just glucose targets

If you have diabetes, assess your cardiac risk and get personalized recommendations with our risk assessment tool.